David Meek

David Meek (born September 12, 1963) is an American businessman. He held various global executive positions in major pharmaceutical and biotechnology companies.[1]

David Meek
CEO of Mirati Therapeutics
Assumed office
2021
CEO of FerGene
In office
2020–2021
CEO of Ipsen
In office
2016–2019
Succeeded byAymeric Le Chatelier
Personal details
Born
David Meek Jr

(1963-09-12) 12 September 1963
NationalityAmerican
EducationUniversity of Cincinnati

In July 2016, the board of directors of Ipsen (Euronext: IPN), a French pharmaceutical company, appointed Meek as chief executive officer. In December 2019, Meek announced his resignation from the position as CEO to take the roles of President and chief executive officer of FerGene in January 2020. In September 2021, he became the chief executive officer of Mirati Therapeutics.

Early life

David Meek attended University of Cincinnati. There, he enrolled in the ROTC program, and after university, served in Operation Desert Storm as a second lieutenant. He served for five years.[2]

Career

In January 2001, he began his career as national field sales director CNS and primary care in Janssen Biotech, Pharmaceutical Companies of Johnson & Johnson (until December 2004 based in Titusville, New Jersey).

He later joined Novartis Pharmaceuticals ($NVS), where he ran the company's respiratory and dermatology franchise in Switzerland (January 2005 – June 2007) before heading up operations in Canada (CEO & president, June 2007 – January 2010) [3] and later running its oncology business in Europe (January 2010 – August 2012).

He has not only been in the pharmaceutical industry, however, and before joining Baxter he was the COO of Endocyte ($ECYT) from August 2012 to July 2014, based in Indianapolis.[4][5][6]

He later joined Baxter International Inc. as head of oncology division (July 2014 – June 2015, based in Cambridge, Massachusetts).

He was executive vice-president and president of the oncology division of Baxalta Inc., which was recently acquired by Shire (July 2015 – July 2016 based in Cambridge, Massachusetts).[7][8][9]

In July 2016, the board of directors of Ipsen (Euronext: IPN; ADR: IPSEY) appointed Meek as chief executive officer, effective July 18, 2016.[10][11][12][13][14]

In December 2019, Meek resigned as CEO of Ipsen to become president and CEO of the newly founded FerGene in January 2020, which is based in Cambridge, Massachusetts, and is a subsidiary of Ferring Pharmaceuticals which is a biopharmaceutical company based in Saint-Prex, Switzerland.[15][16][17]

In April 2021, after FerGene's struggling performance, Meek left FerGene and would later become the CEO of Mirati Therapeutics in September 2021, which is based in San Diego, California.[18][19]

References
  1. "David Meek biography". Bloomberg. Retrieved 2016-08-16.
  2. "Executive Profile: David Meek's mandate is simple: Build Cambridge's next cancer-drug giant". Boston Business Journal. Retrieved 2022-09-25.
  3. "David Meek, CEO Novartis Canada". Canada's research. Retrieved 2008-10-16.
  4. "Endocyte Appoints David Meek to Newly Created Position of Chief Commercial Officer". Endocyte. Retrieved 2012-07-26.
  5. "David Meek leaves Novartis to join Endocyte as first chief commercial officer". PMlive. 30 July 2012. Retrieved 2012-07-30.
  6. "Endocyte appoints Novartis vet David Meek as chief commercial officer". Center watch. Retrieved 2012-07-29.
  7. "Baxalta's oncology chief builds out company's third leg". Medical marketing and media – Larry Dobrow. 18 December 2015. Retrieved 2015-12-18.
  8. "Baxalta: The fastest-growing oncology drug 'startup' in Kendall Square". Boston business journal. Retrieved 2015-12-11.
  9. "David Meek, president of oncology division of Baxalta". Baxalta. Retrieved 2015-07-11.
  10. "Ipsen Names David Meek CEO". Nasdaq. Retrieved 2016-07-11.
  11. "David Meek appointed CEO Ipsen". Pharma Forum – Richard Staines. Retrieved 2016-08-16.
  12. "After Baxalta-Shire merger, David Meek lands CEO job at leaderless Ipsen". Fiercebiotech – Ben Adams. Retrieved 2016-07-11.
  13. "David Meek appointed as Chief Executive Officer of Ipsen" (Press release). Business Wire. 11 July 2016. Retrieved 2016-08-16.
  14. "Ex-Baxalta exec David Meek takes Paris-based helm for Ipsen". Endpoints news – John Carroll. Retrieved 2016-07-11.
  15. "Ipsen Announces Departure of David Meek as Chief Executive Officer". Ipsen. Retrieved 2022-09-25.
  16. "FerGene Appoints David Meek Chief Executive Office". FerGene. Retrieved 2022-09-25.
  17. "An Interview With Brad Hartman From FerGene". Medical Science Liaison Society. 17 March 2020. Retrieved 2022-09-25.
  18. "Fresh off FerGene's meltdown, David Meek takes over at Mirati with lead KRAS drug racing to an approval". Endpoint News. Retrieved 2022-09-25.
  19. "Mirati Therapeutics Appoints David Meek as Chief Executive Officer". Mirati Therapeutics. Retrieved 2022-09-25.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.